Incyte Enters Into Licensing Agreement With Morphosys

“The pooling of Incyte`s know-how and MorphoSys` commitment to innovation will enable us to make Tafasitamab accessible to cancer patients after admission,” said HervĂ© Hoppenot, CEO of Incyte. “We look forward to working closely with the MorphoSys team and including Tafasitamab in our portfolio of oncology candidates as part of our commitment to providing patients and the clinical community around the world with new advanced treatments.” Experts have extracted 7 shares from the list of 220 Z Zacks Rank #1 Strong Buys which beat the market over 2X with a staggering average profit of 24.3% per year. These 7 were selected because of their superior immediate triggering potential. Dr. Michael Booth Division Vice President, Investor Relations – Corporate Responsibility Tel: 1 302 498 5914mbooth@incyte.com The U.S. Food and Drug Administration (FDA) recently launched the submission of the MorphoSys Biologics License (BLA) application, which has accepted tafasitamab in combination with lenalidomide for the treatment of patients with diffuse b-cell lymphoma in relapse or refractory (r/r DLBCL) and has prioritized. The target date of the Prescription Drug User Fee Act (PDUFA) is 30. MorphoSy`s Forward-Looking Statements This communication contains certain forward-looking statements regarding the MorphoSys Group, including expectations regarding the Tafasitamab Licensing Agreement, further clinical development of Tafasitamab, interactions with regulators and expectations regarding regulatory applications and tafasitamab approvals, as well as possible future communittarization of Tafasitamab. Its forward-looking statements constitute The judgment of MorphoSys at the time of this publication and involve known and unknown risks and uncertainties, results, financial condition and liquidity, Performance or Performance of MorphoSys or Industry Results could differ materially from historical or future results, financial conditions and liquidity, performance or performance expressed or implied by such forward-looking statements. While MorphoSys` results, performance, financial position and liquidity and the evolution of the industry in which it operates are consistent with such forward-looking statements, they may not be predicted for results or developments in future periods. Factors likely to cause differences include MorphoSys` expectations regarding the Tafasitamab licensing agreement, the continuation of Tafasitamab`s clinical development, interactions with regulators and expectations regarding regulatory submissions and possible tafasitamab approvals, as well as the future commercialization of Tafasitamab, Morphos` dependence on cooperating with third parties, estimating the commercial potential of its development programs and other risks identified in the risk factors of MorphoSys` annual report on Form 20 F and other applications with the U.S. Securities and Exchange Commission,